Scientists create first mathematical model that predicts immunotherapy success

November 8, 2017, The Mount Sinai Hospital
Axial CT image with i.v. contrast. Macrocystic adenocarcinoma of the pancreatic head. Credit: public domain

Researchers at the Icahn School of Medicine at Mount Sinai have created the first mathematical model that can predict how a cancer patient will benefit from certain immunotherapies, according to a study published in Nature.

Scientists have long sought a way to discover whether patients will respond to new checkpoint inhibitor immunotherapies and to better understand the characteristics that indicate a can be successfully treated with them. The proposed , which captures aspects of the tumor's evolution and the underlying interactions of the tumor with the immune system, is more accurate than previous genomic biomarkers in predicting how the tumor will respond to immunotherapy.

"We present an interdisciplinary approach to studying immunotherapy and of tumors," said Benjamin Greenbaum, PhD, the senior author, who is affiliated with the departments of Medicine, Hematology and Medical Oncology, Pathology, and Oncological Sciences at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai. "This approach will hopefully lead to better mechanistic predictive modeling of response and future design of therapies that further take advantage of how the immune system recognizes tumors."

This novel also has the potential to help find new therapeutic targets within the immune system and to help design vaccines for patients who do not typically respond to immunotherapy.

To create this model, researchers used data from melanoma and being treated with immune checkpoint inhibitors. The model tracked many properties within the to the drugs, particularly neoantigens, which are specific to mutating and growing tumors.

Neoantigens have the potential to be prime immunotherapy targets, and the proposed framework will likely be useful in studies of acquired resistance to immunotherapy and may be crucial for understanding the circumstances in which causes autoimmune-like side effects.

The first author of the study is Marta Luksza, PhD, a computer scientist from the Simons Center for Systems Biology at the Institute for Advanced Study. Dr. Greenbaum and Dr. Luksza also played an integral role in a companion piece of research led by researchers Vinod P. Balachandran, MD, Taha Merghoub, PhD, and Steven D. Leach, MD, at Memorial Sloan Kettering Cancer Center (MSK) that was also published in Nature today. That study showed how a similar model can be used to understand immune response in patients with pancreatic who survive longer than others. Both studies demonstrate that this is a likely path forward to understanding when the immune system will lead to productive recognition of a tumor.

"This research represents a big step forward in understanding why some tumors are more aggressive than others and being able to predict rationally which neoantigens will be the most effective at stimulating an immune response," said Dr. Balachandran, a member of the David M. Rubenstein Center for Pancreatic Cancer Research at MSK, and corresponding author of the companion study in Nature.

Explore further: DNA mutations shed in blood predicts response to immunotherapy in patients with cancer

More information: A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy, Nature (2017). nature.com/articles/doi:10.1038/nature24473

Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer, Nature (2017). nature.com/articles/doi:10.1038/nature24462

Related Stories

DNA mutations shed in blood predicts response to immunotherapy in patients with cancer

October 2, 2017
In a first-of-its-kind study, University of California San Diego School of Medicine researchers report that a blood sample, or liquid biopsy, can reveal which patients will respond to checkpoint inhibitor-based immunotherapies.

Drug combination may improve impact of immunotherapy in head and neck cancer

September 21, 2017
Checkpoint inhibitor-based immunotherapy has been shown to be very effective in recurrent and metastatic head and neck cancer but only in a minority of patients. University of California San Diego School of Medicine researchers ...

Colorectal cancers may mutate to escape immune system detection in many ways

October 30, 2017
Whole exome sequencing revealed that colorectal cancers with high mutational load (MSI-H) predominantly use "immunoediting" to escape immune surveillance while colorectal cancers with low mutational load (MSS) use oncogenic ...

Study sheds light on why some breast cancers have limited response to immunotherapy

August 21, 2017
UNC Lineberger Comprehensive Cancer Center researchers have identified a possible reason why some aggressive breast cancers are unresponsive to certain immunotherapy treatments, as well as a potential solution.

Researchers identify immunotherapy targets in early-stage lung cancer

May 4, 2017
Immunotherapy, which has achieved remarkable results in late-stage lung cancer patients, can also hold great hope for newly diagnosed patients, cutting the deadly disease off before it has the chance to take hold and offering ...

Cancers evade immunotherapy by 'discarding the evidence' of tumor-specific mutations

January 5, 2017
Results of an initial study of tumors from patients with lung cancer or head and neck cancer suggest that the widespread acquired resistance to immunotherapy drugs known as checkpoint inhibitors may be due to the elimination ...

Recommended for you

Study demonstrates new treatment for severe asthma

May 22, 2018
Researchers from McMaster University and the Firestone Institute for Respiratory Health at St. Joseph's Healthcare Hamilton, together with colleagues at other partnering institutions, have developed a new method to treat ...

Eczema drug effective against severe asthma

May 21, 2018
Two new studies of patients with difficult-to-control asthma show that the eczema drug dupilumab alleviates asthma symptoms and improves patients' ability to breathe better than standard therapies. Dupilumab, an injectable ...

Neuron guidance factor found to play a key role in immune cell function

May 21, 2018
Macrophages are white blood cells involved in a variety of biological functions, from destroying infectious pathogens to repairing damaged tissue. To carry out their different roles, macrophages must first be activated and ...

Immune cells hold promise in slowing down ALS

May 21, 2018
Recent research from Houston Methodist Hospital showed that a new immunotherapy was safe for patients with ALS and also revealed surprising results that could bring hope to patients who have this relentlessly progressive ...

First clues to the causes of multiple sclerosis

May 16, 2018
Multiple sclerosis, which affects one in 1,000 people, is frequently characterised by relapses associated with variable functional impairments including among others vision problems, impairment of locomotor functions or difficulties ...

A high-fiber diet protects mice against the flu virus

May 15, 2018
Dietary fiber increases survival in influenza-infected mice by setting the immune system at a healthy level of responsiveness, according to a preclinical study published May 15th in the journal Immunity. A high-fiber diet ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.